Drug Profile
Acorafloxacin
Alternative Names: Avarofloxacin; JNJ-32729463; JNJ-32729463-AAA; JNJ-Q2Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Janssen
- Developer Furiex Pharmaceuticals; Janssen
- Class Antibacterials; Carboxylic acids; Fluorocarbons; Fluoroquinolones; Piperidines; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Community-acquired pneumonia; Skin and soft tissue infections
Most Recent Events
- 07 May 2014 Avarofloxacin is available for licensing as of 07 May 2014. http://www.furiex.com
- 25 Feb 2013 Avarofloxacin receives Fast Track designation for Skin and soft tissue infections and Community-acquired pneumonia in USA
- 25 Feb 2013 Avarofloxacin receives Qualified Infectious Disease Product (QIDP) designation from the US FDA for Skin and soft tissue infections and Community-acquired pneumonia